Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. (November 2016)

• Record Type: Journal Article
• Authors: Nanah, Rama; Zblewski, Darci; Patnaik, Mrinal S.; Begna, Kebede; Ketterling, Rhett; Iyer, Vivek N.; Hogan, William J.; Litzow, Mark R.; Al-Kali, Aref
• Is Part Of: Leukemia research. Volume 50(2016:Nov.)
• Page Start: 112
• Page End: 115
• Publication Date: 2016-11
• Subjects: Interstitial lung disease -- Myelodysplastic syndrome -- Azacitidine -- Hypomethylating agents -- Lenalidomide; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2016.10.002
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: ILD is seen more frequent than anticipated in MDS. Deletion 5q was frequent in MDS patients with ILD. No evidence of increased autoimmunity was seen in MDS patients with ILD. Abstract: A variety of interstitial Lung Diseases (ILD) have been described in patients with myelodysplastic syndromes (MDS) with possible etiologies including autoimmunity, drug related toxicity, and recurrent infections. A comprehensive study of ILD in MDS patients has not been previously performed. Out of 827 consecutive biopsy proven MDS patients seen at our institution from June 1970–May 2010, 18 (2%) were found to have ILD. There was no statistical significance in baseline characteristics between patients with ILD (ILD +) vs those without ILD (ILD−). Cytogenetic studies were reported in 14 ILD + patients out of whom 43% had 5q- abnormalities (21% isolated and 22% part of complex karyotype). Prevalence of high risk MDS was similar between both groups (22% vs 29% in ILD−) with similar overall survival. ILD was diagnosed prior to MDS in the majority of cases (72%) with a median time to MDS diagnosis of 22.3 months. Our study suggests that ILD are present in a higher percentage than anticipated in the MDS population. Deletion 5q was frequent in ILD+ cases and this requires further study. Prior MDS treatment and autoimmunity seemed to play no significant role in ILD development.